Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Platelet aggregation behaviour in patients treated with ticlopidine.

A S Petronio, L Evangelisti, R Preti

Drugs Under Experimental and Clinical Research

|January 1, 1987

Summary

Ticlopidine effectively reduced platelet aggregation in atrial fibrillation patients, showing superior results compared to dipyridamole plus aspirin. This antiplatelet drug demonstrated efficacy without causing embolic events over six months.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to "Impact of hemoglobin levels at admission on outcomes among elderly patients with acute coronary syndrome treated with low-dose Prasugrel or clopidogrel: A sub-study of the ELDERLY ACS 2 trial" [Int J Cardiol. 2022 Dec 15;369:5-11].

International journal of cardiology·2023

Same author

Probing intra- and inter-molecular interactions through rotational spectroscopy: The case of the odorant 2'-aminoacetophenone and its 1:1 water and neon complexes.

The Journal of chemical physics·2022

Same author

Clinical impact and evolution of mitral regurgitation after TAVI using the new generation self-expandable valves.

International journal of cardiology·2021

Same author

Reply letter to Dr. Xu et al. on role of circulating endothelial progenitor cells in the reparative mechanisms of stable ischemic myocardium.

International journal of cardiology·2018

Same author

Role of circulating endothelial progenitor cells in the reparative mechanisms of stable ischemic myocardium.

International journal of cardiology·2017

Same author

Prediction of patient-specific post-operative outcomes of TAVI procedure: The impact of the positioning strategy on valve performance.

Journal of biomechanics·2016

Area of Science:

Cardiology
Hematology
Pharmacology

Background:

Atrial fibrillation poses a significant risk for thromboembolic events.
Antiplatelet therapy is crucial in managing atrial fibrillation patients.
Evaluating novel antiplatelet agents like ticlopidine is essential.

Purpose of the Study:

To assess the antiplatelet effects of ticlopidine on platelet aggregation.
To determine ticlopidine's efficacy in preventing thromboembolisms.
To monitor side-effects and hematological parameters during treatment.

Main Methods:

A 6-month study involving 30 patients with atrial fibrillation treated with ticlopidine.
Comparative analysis of ticlopidine versus dipyridamole + aspirin in 20 patients.

Related Experiment Videos

Regular monitoring of hematological parameters, platelet aggregation (ADP-induced), bleeding time, and echocardiograms.

Main Results:

Ticlopidine significantly reduced adenosine diphosphate (ADP)-induced platelet aggregation.
Ticlopidine demonstrated superior antiplatelet activity compared to dipyridamole + aspirin.
Increased bleeding time and reduced platelet adhesivity were observed; side-effects occurred in 33.3% of patients.
No thromboembolic events or left atrial thrombosis were detected.

Conclusions:

Ticlopidine is an effective antiplatelet agent for patients with atrial fibrillation, particularly those with hyperaggregation.
The drug shows promise in preventing thromboembolic complications.
Ticlopidine appears to be a viable therapeutic option with manageable side effects.